Proposed Medicaid policy changes, including outcome-based and annuity payment models, aim to enhance access to costly cell and gene therapies (CGTs) while addressing state budget constraints[6]. These changes could alleviate immediate financial burdens by spreading costs over time and tying payments to patient outcomes[6].
Current reimbursement models often leave states with stringent utilization controls, limiting access to innovative treatments, particularly for high-cost therapies[5]. If successfully implemented, these policy adjustments could not only reduce hospital budget impacts but also enhance patient access to essential therapies that address severe health conditions[3].
Get more accurate answers with Super Search, upload files, personalized discovery feed, save searches and contribute to the PandiPedia.
Let's look at alternatives:
- Modify the query.
- Start a new thread.
- Remove sources (if manually added).
- Request a manual search from our human research team.
